ESH CLL – Lukas P. Frenzel

Lukas P. Frenzel summarizes the latest insights into resistance mechanisms to commonly used drugs such as BTK inhibitors and venetoclax. He explains how this knowledge affects daily clinical practice and/or proper patient selection, how patients can be handled who are resistant to both BTK and BCL2 inhibitors and highlights the role of MARCKS in fine-tuning responses to the BTK inhibitors. 

Here is the full ESH CLL 2022 report.